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Stlmln~'y 
B and T  cell responses  of several strains  of mice, immunized with a monodonal antiidiotype 
(anti-Id) that mimics the a determinant of hepatitis B surface antigen (HBsAg), were studied 
to determine ff the immune response to the anti-Id was regulated by H-2-1inked immune response 
genes as has been previously observed for HBsAg. We report that immunization with anti-Id 
could elicit HBsAg-spedfic antibodies in mice of the H-2a,q  , or f haplotype and in an outbred 
wild mouse strain (Mus spretus), thus drcumventing the H-2 haplotype restriction pattern observed 
when immunizing with HBsAg in H-2  f mice. Purified lymph node T  cells from mice of the 
H.2  a or q haplotype and M. spretus that were primed in vivo with HBsAg or anti-Id could be 
stimulated in vitro with either HBsAg or anti-Id but not with an irrelevant  antibody of the 
same subclass as the anti-Id. However, purified lymph node T  ceils from H-2  f mice that were 
primed in vivo with the anti-Id could only be stimulated in vitro with anti-Id. No in vitro 
stimulation whatsoever was observed in H-2  f mice immunized with HBsAg.  The effect of 
processing and presentation of the anti-Id by antigen-presenting cells (APC) was studied in mice 
of the H-2  a haplotype. Stimulation of purified lymph node T cells by HBsAg and anti-Id was 
shown to be strictly dependent on APC and restricted by major histocompatibility complex class 
II antigens at the I-A locus. Treatment of APC with paraformaldehyde or chloroquine abrogated 
the T cell response to all antigens except for a nine-amino acid synthetic peptide representing 
a partial analogue of the group a determinant of HBsAg S(139-147).  The significance of these 
results is discussed in the context of understanding the mechanism of mimicry dicited by the anti-Id. 
nalogous to the situation with HIV, there is no inbred 
animal model for hepatitis B virus (HBV)  1 infection 
and therefore most studies have evaluated HBV proteins as 
immunogens rather than as infectious agents. Extensive work 
by Milich (1) and others has established that the murine im- 
mune response to the group-specific a determinant of hepa- 
titis B surface antigen (HBsAg) is H-2 restricted and shows 
a hierarchy of responsiveness at the B and T cell level The 
hierarchy of the humoral response to HBsAg is as follows: 
high responders, H-2q,d; intermediate responders, H-2' > 
H-2  b > H-2k; and nonresponders,  H-2  *.f. The T cell prolifer- 
ative response to HBsAg generally paralleled  the same H-2 
restriction observed for the humoral response. 
For the study of immune responses to HBV, we produced 
anti-Ids against a mouse mAb, designated H3F5 (2) (Id, Abl), 
1 Abbreviations  used in this paper: I--IBsAg,  hepatitis B surface antigen; HBV, 
hepatitis B virus. 
which recognizes the protective a determinant epitope on 
HBsAg. The fusion of spleen cells obtained from BALB/c 
mice immunized with H3P5 resulted in six monoclonal anti- 
Ids. All of them inhibited the binding of HBsAg to the H3F5 
Id, however, ordy two of these anti-Ids (designated as 2F10 
and 4D4) recognized an interspecies crossreactive  Id, as demon- 
strated by the reaction of these bybridomas with polyclonal 
anti-HBs sera from a variety of species (3, 4).  Since the a 
determinant on HBsAg is important in conferring protec- 
tion (5), we therefore wanted to determine whether our anti- 
Ids carried an internal image of the a determinant. To test 
this, anti-HBs sera (ad or ay specific) were adsorbed with 
HBsAg ad or ay. Only adsorption of antibodies against the 
a determinant abolished reactivity of the polyclonal sera with 
the anti-Ids (3, 4). 2F10 and 4D4 were therefore tentatively 
classified as "internal image" anti-Ids (Ab2/~), and one of these 
anti-Ids (2F10) was further studied to determine if it could 
mimic HBsAg and generate specific B and T call responses. 
We report here that immunization with the anti-Id 2F10 could 
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antigen it mimics, are not restricted by a known HBsAg non- 
responder haplotype. 
Materiah and Methods 
Animals.  BALB/c  mice  (H-2  a)  were  obtained  from  West 
Seneca Labs (West Seneca, NY).  B10.M(H-2  f) and SWIL(H-2q) 
were obtained from The Jackson Laboratory (Bar Harbor, ME). 
Wild mice, Mus spretus, were a kind gift from Dr. Veme Chapman 
(Roswell Park Cancer Institute). All mice were female and 6-8 wk 
old at the start of the study. 
In Vivo and In Vitro Stimuli.  2F10 is a mouse monodonal in- 
ternal image anti-Id of the IgG1 subclass that has been shown to 
mimic the group-specific a determinant of HBsAg. 2F10 aseites 
was purified by 45% ammonium sulphate precipitation followed 
by passage over a protein A column. 2F10 Fab was prepared by 
digestion of the purified anti-Id with immobilized papain followed 
by a protein A-Sepharose column to remove Fc fragments and any 
undigested  IgG,  according to manufacturer's  directions (Pierce 
Chemical Co., Rockford, IL). Separation of anti-Id 2F10 into H 
and L chains was performed essentially as described elsewhere (6), 
except dithiothreitol was used as the reducing agent. The routine 
mAb 2C3 (specific for the hapten phthalate) has the same subclass 
as 2F10 and was used as a control throughout this study (kindly 
provided by Dr. S. Ghosh, Indiana State University, Terre Hante, 
IN). HBsAg is the outer envelope protein of the hepatitis B virus. 
rHBsAg and rHBsAg-alum devoid of pre-S proteins were gener- 
ously provided by Dr. W. E Miller (Merck, Sharp and Dohme Re- 
search Laboratories,  Westpoint, PA). A nine-amino acid synthetic 
peptide (CTKtrrDGNC) that represents a partial analogue of the 
group-specific a determinant located in the S region (139-147) of 
HBsAg (7) was used as a positive control in antigen processing 
experiments. The peptide was synthesized as a COOH-terminal 
amide, and the purity (>80%) was assessed by HPLC using a Vydac 
C-18 column (Multiple Peptide Systems, San Diego, CA). The con- 
trol peptide used in these experiments was either a variant of the 
S(139-147) peptide (CTKPSDRNC; this peptide was previously 
shown to abrogate T cell proliferative responses to murine T cells 
that were primed with rHBsAg [8]) or a 15-amino acid peptide 
from a sequence of  yellow fever virus (GAMRVTKDTNDNNLY). 
Induction of Anti-HBs Antibodies.  Mice (five/group) were im- 
munized intraperitoneally on days 0, 7, and 14 with either rHBsAg, 
2F10 anti-Id, or control antibody 2C3. rHBsAg was administered 
as an alum-adsorbed precipitate at a dose of 0.5/~g/animal per in- 
jection. 2F10 anti-Id or control mAb was administered at 100/,tg/an- 
imal per injection in CFA, IFA, and saline, respectively. Mice were 
bled retro-orbitally and the sera evaluated for anti-HBs-specific an- 
tibodies using a commercially available ELISA kit (AUSAB; Ab- 
bott Diagnostic Laboratories,  Chicago, IL). 
Isotype Distribution of the Anti-HBs Response.  The isotype dis- 
tribution of the anti-HBs response was determined using the Mouse 
Typer sub-isotyping kit (Bio-Rad Laboratories,  Richmond, CA). 
Sen were diluted in PBS-0.05% Tween 20 and incubated on HBsAg- 
coated beads for 2 h. The beads were washed and a 1:2 dilution 
of rabbit anti-mouse subclass-specific antiserum was added for 1 h. 
The beads were washed again and a 1:3,000 dilution of goat anti- 
rabbit horseradish peroxidase conjugate was added.  After 1 h the 
beads were washed and developed in a peroxidase substrate solu- 
tion (2,2'-amino-di[3-ethyl-benzthiazoline sulfonate]  and H202) 
for 30 rain and results read on an automated EIA reader at 405 
nm. The entire assay was performed at room temperature and every 
wash step consisted of five washes  in PBS-Tween 20. 
In Vitro Proliferation of  Mouse Lymph Node T Cells.  Mice (five/ 
group) were immunized in the hind foot pads with either rHBsAg, 
anti-Id 2F10, or control monoclonal 2C3. Amount of antigen ad- 
ministered and schedule of immunization are the same as described 
above for the induction of anti-HBs antibodies.  It may seem at first 
that out method of immunization for the induction of T cell re- 
sponses is quite unorthodox (immunizing three times in the footpad 
vs. a tingle injection). We, however, only use 0.5/~g of rHBsAg 
per injection. This is substantially below the doses that are reported 
in the literature, where a single injection of 16/~g of HBsAg was 
administered and T cells collected 8-10 d later (9, 10). 1 wk after 
the third injection the animals were kilhd and the popliteal lymph 
nodes were collected, teased apart, and the ceils washed twice in 
ILPMI 1640 supplemented with 2 mM L-glutamine, 100 U/m1 pen- 
icillin,  100/~g/ml streptomycin, 50/~g/ml gentamicin, 0.2 mM 
nonessential amino acids, 11/~g/ml sodium pyruvate, 0.02 M Hepes, 
and 5  x  10 -s 2-ME (incomplete media), and once in complete 
media (incomplete media supplemented with 10% heat-inactivated 
FCS).  T  cell  enrichment was  performed at  10  s cells/0.6  g  of 
packed nylon wool (Cellular Products, Buffalo, NY). After enrich- 
ment, T cells were >97% pure as measured by staining with anti- 
Thy-l.2 antibody conjugated to FITC. The enriched T ceils were 
adjusted to a concentration of 2.5  x  105 cells/well.  100 #1 of cells 
was phted in 96-well flat-bottomed plates along with 5  x  10  s ir- 
radiated syngeneic spleen cells as a source of APC.  Appropriate 
concentrations of the different stimuli diluted in complete media 
(100/~l/well) were added to the cells in triplicate cultures. The 
stimuli were: rHBsAg (0.1 or 0.5/~g/well), 2F10 anti-Id and iso- 
type  control  antibody  (20  or  50  /~g/well),  synthetic  peptide 
S(139-147) and control peptide (0.05 or 0.10/~g/well), Con A (1 
/~g/well),  or media alone. The cells were then cultured for 120 h 
in a 5.5%  CO2 incubator at 37~  [3H]TdR  (1 /~Ci/well)  was 
added to each well 18 h before the end of the culture period. The 
cells were harvested onto glass fiber filters using an automatic cell 
harvester (seatron,  Sterling,  VA). Proliferation, as measured by 
[3H]TdR incorporation,  was  determined by liquid  scintillation 
spectroscopy.  Results are expressed as the mean cpm of [~H]TdR 
incorporation of triplicate wells. 
MHC Class II Restriction.  To determine the MHC class II re- 
striction in  our system,  we treated BALB/c (H-2  a) APC  with 
mAbs MK-D6 or 34-1--4S, which are specific for I-A  d and I-E  d, 
respectively. The MK-D6 and 34-1-4S cell lines were obtained from 
American Type Culture Collection (Rockville,  MD).  2  x  107 
APC were incubated with 500 ~1 of either MK-D6 or 34-1-4S 
culture supematant for 1 h at 4~  with shaking. The ceils were 
then washed three times in incomplete media. These APC were 
immediately used in in vitro T call experiments as described pre- 
viously. 
Chloroquine and Paraformaldeh,/de Treatment of APC.  In experi- 
ments directed towards studying the role of antigen processing, 
spleen cells (as a source of APC) were treated essentially according 
to the procedure of Kovac and Schwartz (11). 3  x  107 APC were 
incubated for 20 rain with 2 ml of either 0.3 M chloroquine or 
0.5% (wt/vol) paraformaldehyde.  The cells treated with chloro- 
quine were washed four times in incomplete media and the cells 
treated with paraformaldehyde were washed five times in cold com- 
plete media. After this treatment the APC were set up in in vitro 
T cell experiments as described above. 
Results 
Anti-HBsAg Production by rHBsAg or Anti-Id.  As shown 
in Fig. 1, A  and B, both SWR/J (H-2q) and BALB/c (H-2  a) 
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rHBsAg-alum, however,  the B10.M  strain (H-2  f) did not 
(Fig. 1 C), thus confirming earlier reports by other investi- 
gators on the classification of the B10.M strain as a nonre- 
sponder to HBsAg (12). The outbred wild mice, M. spretus, 
also made a strong anti-HBs response when injected with 
rHBsAg-alum (data not shown). Importantly, in all the above 
mouse strains (BALB/c, SWP,/J, B10.M, and M. spretus), an 
anti-HBs response was dicited when the mice were injected 
with the monoclonal internal image anti-Id 2F10 (Fig.  1, 
A-C). Thus, our anti-Id was successful in circumventing non- 
responsiveness to the a determinant of HBsAg in the B10.M 
mouse strain. 
Isotype Distribution of Anti-HBs Responses.  An analysis of 
the isotype distribution of the anti-HBs response showed that 
both anti-Id and rHBsAg induced responses in the BALB/c 
mice that were predominantly of the IgG1 subclass (Table 
1). Additionally, the rHBsAg-immunized BALB/c mice pro- 
duced a substantial amount of IgG2b and lesser amounts of 
IgG2a and IgM anti-HBs-specific  antibodies. In sera from 
2F10-immunized BALB/c mice coUected at a later time point 
(3-5 wk after the third immunization), we also detected small 
amounts of IgG2b and IgM anti-HBs-specific  antibodies. In 
contrast to the responses observed in BALB/c mice immunized 
with the anti-Id 2F10, B10.M mice produced predominantly 
anti-HBs antibodies of the IgG2b subclass and some IgG1 
antibody. 
In  Vitro Proliferation of HBsAg- or Anti.Id-primed T  Cells. 
Purified T cells obtained from the popliteal lymph nodes of 
mice primed in vivo with rHBsAg were stimulated in vitro 
for 120 h with varying concentrations of anti-Id, control an- 
tibody, rHBsAg, a synthetic peptide corresponding to residues 
139-147 of the S region protein of HBsAg, control peptide, 
or media alone (Table 2).  As previously shown by others, 
T ceUs from B10.M mice injected with HBsAg do not re- 
spond in vitro to HBsAg (13), and as seen in our experiments, 
these T cells also do not respond in vitro to the anti-Id. T 
ceUs obtained from  the  two  other  strains  (BALB/c  and 
SWR/J) primed with rHBsAg responded in vitro to both 
rHBsAg and anti-Id 2F10 (Table 2). Thus, the and-Id is capable 
of efficiently stimulating in a specific manner T  cells from 
rHBsAg-primed mice. Good proliferative responses were also 
observed in vitro with a synthetic nine-amino acid peptide 
(S[139-147]) that corresponds to a determinant residues  of 
HBsAg. 
In reciprocal experiments, T calls were obtained from mice 
primed in vivo with 2F10 anti-Id and stimulated in vitro with 
various  stimuli. Table 3 shows that T  cells obtained from 
BALB/c, SWR/J, B10.M, and M. spretus primed in vivo with 
anti-Id can respond in vitro to the anti-Id. More importantly, 
T calls primed in vivo by the anti-Id do proliferate in vitro 
to rHBsAg (except the B10.M strain). This result is significant 
if this anti-Id were to be used as an alternative vaccine to 
HBsAg. The lack of proliferation observed in cultures of T 
cells obtained from B10.M mice immunized with the anti-Id 
is not likely a reflection of an attenuated B cell response in 
these animals.  Though the results of a longitudinal study 
of anti-HBsAg responses in three strains of mice (Fig. 1) sug- 
gests that B10.M mice make a weaker antibody response, we 
in fact have additional results (data  not shown), wherein, 
B10.M mice immunized in the footpad with the anti-Id do 
make equivalent antibody response to those seen in BALB/c 
mice. However, even when using cells from these animals, 
no T  cell response to rHBsAg could be elicited. 
A  Balb/c (H-2  d)  B  SWR/J (H-2 q) 
d ~ I  0  o.4 
￿9 0.0~  m  m  m 
Injections  Weeks Post Third Immunization  Injections  Weeks Post Third Im  un  Ion 
1.0 
0  0.8 
U) 
0.6 
(~  0.4 
0.2 
0 
C BIO.M (1t-2 f ) 
Weeks Post Third Immunlzatlon 
InJeclion,, 
129  Pride et al. 
Figure 1.  Comparison of anti- 
HBs antibody responses elicited by 
immunization  with  anti-Id  (ll) 
or  rHBsAg  (e)  in  (A)  BALB/c 
(H-2d), (13) SWp./J (H-Zq), or (C) 
B10.M  (H-2f).  Results  are  ex- 
pressed as OD 492:660  of the av- 
erage of five mice per group at ei- 
ther a 1:20 dilution (SWR./J and 
BALB/c) or 1:5 dilution (B10.M) of 
their sera. Table  1.  Isotype Distribution of Anti-HBs Responses 
Mouse  Immunogen  IgG1  IgG2a  IgG2b  IgG3  IgM 
BALB/c  None*  0.042  0.035  0.041  0.048  0.047 
(H-2  a)  2F10~  1.289  0.069  0.020  0.075  0.097 
2F10  s  0.919  0.080  0.180  0.033  0.126 
2C3 II  0.064  0.041  0.058  0.069  0.064 
HBsAg~  1.686  0.219  0.814  0.095  0.238 
B10.M  None*  0.027  0.004  0.045  0.008  0.032 
(H-2~  2F10'  0.245  0.026  0.892  0.089  0.096 
2C3"*  0.048  0.022  0.032  0.065  0.052 
HBsAgU  0.040  0.039  0.028  0.035  0.027 
Comparison of the isotype distribution of the anti-HBs response in BALB/c and B10.M mice immunized with anti-Id 2F10, isotype control antibody 
2C3, or rHBsAg. Sera were collected 1 wk after the third injection (unless indicated otherwise) and tested at a 1:50 dilution. Results are expressed 
as OD at 405 rim. 
* Pooled normal sera. Values are the average of four separate experiments. 
Values represent the average of six mice. 
s Values represent the average of sera from one mouse bled 3,  4, and 5 wk after the third injection. 
II Values represent the average of two mice. 
￿82  Values represent the average of sera from two mice bled 3, 4,  and 5 wk after the third injection. 
** Values represent the average of three mice. 
The nine-amino acid synthetic peptide S(139-147) was also 
able to dicit a response in vitro in BALB/c,  SWR/J,  and 
M. spretus (Table 3),  again confirming the a  determinant 
specificity of the response that our anti-Id is able to generate. 
Table  2.  In  Vitro Proliferation of HBsAg-priraed T  Cells 
BALB/c  SWR/J  B10.M 
Stimulus  Concentration  (H-2  d  )  (H-2q)  (H-2  f) 
/~  g /well 
2F10  20  43,842  54,172  908 
50  66,066  86,121  746 
2F10 Fab  20  ND  54,648  ND 
2F10 H  chain  20  43,812  45,283  ND 
2F10 L  chain  20  4,089  ND  ND 
2C3  20  1,238  296  593 
50  1,248  305  773 
rHBsAg  0.1  49,628  72,044  717 
0.5  41,533  109,513  762 
Peptide  0.05  21,799  45,190  762 
S(139-147)  0.1  27,107  17,307  559 
Control  0.05  408  113  602 
Peptide  0.1  340  469  816 
Media  761  276  823 
HBsAg and 2F10 anti-Id can stimulate in vitro T cells  from mice of differ- 
ent H-2 haplotypes  (except  B10.M) that were primed in vivo with HBsAg. 
Proliferation was assessed  as described in Materials and Methods. Results 
are expressed as the average cpm of [3H]TdR incorporation of either four 
(BALB/c),  two (B10.M), or one (SWR/J) separate experiment. 
The antigenic specificity of the proliferative responses shown 
in both Tables 2 and 3 is controlled by the lack of response 
in the absence of an in vitro stimulus (media alone), but more 
importantly, no response is observed in cultures stimulated 
with an isotype-matched control antibody or a control syn- 
thetic peptide. Additional specificity control was achieved by 
immunizing mice with our isotype-matched  control antibody 
2C3 and performing similar T cell assays as discussed earlier. 
The results in Table 4 show that no stimulation was observed 
with any in vitro stimuli except for the in vivo immunizing 
antibody 2C3. 
To establish  that our anti-Id was not stimulating these 
primed T  cells  nonspecifically  by  TCR  crosslinking, we 
digested the anti-Id into either monovalent Fab fragments 
or separate H and L chains. As seen in Tables 2 and 3, both 
the anti-Id Fab fragments and H chains can stimulate T cells 
that were primed with either HBsAg or anti-Id.  It is in- 
teresting to note that the H chain of the anti-Id stimulates 
these primed T cells very efficiently and probably accounts 
for most of the stimulation seen with the intact anti-Id. 
Processing  and Presentation  of  HBsAg and Anti-Id.  APC are 
necessary for the uptake of complex antigen, degradation of 
the antigen in endosomal compartments into peptide frag- 
ments, and subsequent association of these peptides with MHC 
class II antigens on the surface of the APC. T cells specific 
for a given antigen then recognize this peptide-MHC class 
II complex and respond in in vitro proliferation assays by 
secreting IL-2 and proliferating. Proliferation can therefore 
be blocked by: (a) blocking the uptake of antigen into the 
APC (paraformaldehyde treatment ofAPC); (b) allowing up- 
take of the antigen into the APC but blocking degradation 
of the antigen into appropriate peptide fragments (chloro- 
quine treatment of APC); or (c) blocking the association of 
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BALB/c  SWK/J  B10.M 
Stimulus  Concentration  (H-2  d)  (H-2q)  (H-2  ~)  M. spretus 
/~g/well 
2F10  20  160,495  46,669  35,695  49,068 
50  161,504  54,413  48,494  75,005 
2F10 Fab  20  ND  46,340  ND  54,660 
2F10 H chain  20  ND  34,233  ND  44,746 
2C3  20  2,167  739  441  357 
50  2,483  543  358  645 
rHBsAg  0.1  43,682  42,995  791  46,406 
0.5  52,557  53,953  771  61,225 
Peptide  0.05  21,668  44,840  408  36,548 
S(139-147)  0.1  26,296  32,984  368  22,825 
Control  0.05  1,707  973  560  539 
Peptide  0.1  1,836  699  527  601 
Media  2,255  1,039  420  554 
HBsAg and 2F10 anti-Id can stimulate  in vitro T cells from mice of different  H-2 haplotypes  that were primed in vivo with 2F10 anti-Id. In every 
strain tested 2F10 anti-Id can induce  an anti-HBs response, however, it cannot  prime T ceUs in the B10.M(H-2f) strain that can be recalled in vitro 
by HBsAg. Proliferation  was assessed as described in Materials and Methods. Results are expressed as the average cpm of [3H]TdK incorporation 
of either two (B10.M) or one (BALB/c, SWR/J, M. sI#etus  ) separate experiment. 
the MHC class II antigen-peptide fragment complex to primed 
T  ceUs with antibodies directed towards MHC class II an- 
tigens (anti-I-A or anti-I-E antibody treatment of APC). 
It is known that HBsAg is a T-dependent antigen (14) and 
Table  4.  In  Vitro Proliferation of Isotype Control 
Antibody-primed  T  Cells 
BALB/c 
Stimulus  Concentration  (H-2  d) 
/~g/u, dl 
2F10  20  548 
50  987 
2C3  20  11,066 
50  15,566 
rHBsAg  0.1  40 
0.5  547 
Peptide  0.05  937 
S(139-147)  0.1  1,073 
Control  0.05  1,113 
Peptide  0.1  1,167 
Media  757 
Specificity  control for anti-Id 2F10. BALB/c  mice were primed in vivo 
with isotype-matched  control mAb 2C3 (IgGl,k). Primed  T cells from 
these mice cannot be stimulated  in vitro by either anti-Id or HBsAg. 
Proliferation  was assessed  as described  in Materials  and Methods.  Results 
are expressed as the average cpm of pH]TdR incorporation of two 
separate experiments. 
that the in vitro T cell proliferative responses  to HBsAg are 
dependent upon APC. We therefore set out to determine if 
processing of the anti-Id was necessary before its presenta- 
tion and recognition by primed T ceUs. Treatment of the APC 
with  either chloroquine  or  paraformaldehyde completely 
abrogated the in vitro T ceLl  proliferative responses that were 
induced by priming in vivo with either HBsAg or anti-Id 
(Fig. 2). The response induced by the synthetic nine-amino 
acid peptide S(139-147),  however,  was not affected by this 
treatment and served as a positive control. Although results 
are only shown for T cells obtained from BALB/c mice in- 
jected with rHBsAg, similar results were obtained using anti- 
Id-primed BALB/c T  cells. 
Data in Table 5 are from experiments where BALB/c APC 
(H-2  d) were treated with either mAbs MR-D6  (anti-I-A  d) 
or 34-1-4S (anti-I-Ed).  The results clearly show that the re- 
striction for both anti-Id and HBsAg is imposed by the I-A  d 
locus, as complete abrogation of the response is seen in cul- 
tures where the APC were treated with the anti-I-Aa-spedfic 
antibody. APC treated with anti-I-E  d antibodies were able 
to present HBsAg/anti-Id similar to untreated cultures. Data 
from other  laboratories  have  shown  that both  I-A  a-  and 
I-Ea-encoded  Ia molecules can present HBsAg in BALB/c 
mice (9).  The presence  of APC was critical in our in vitro 
proliferation assay as no stimulation whatsoever was observed 
using rHBsAg/anti-Id-primed T  cells stimulated by either 
antigen or anti-Id in the absence  of APC (Fig.  2). 
Discussion 
The surface envelope of HBV contains three related pro- 
teins designated S, M (S  +  preS2),  and L (M  +  preS1). A11 
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Figure 2.  T cells were obtained from BALB/c mice that were injected 
with rHBsAg and set up in in vitro proliferation assays with the various 
stimuli shown along the x-axis. APC were treated with either chloro- 
quine or paraformaldehyde. As can be seen, both these protocols abrogate 
the in vitro proliferative responses to all stimuli except S(139-147) pep- 
tide. Results are expressed as the average cpm of [SH]TdP, incorporation 
of one experiment.  In the absence of APC no response is observed. 
of these proteins share the 226-amino acid sequence of the 
S protein, which is the major protein of HBsAg. In a well- 
documented series of experiments,  it has been determined 
that the murine B and T cell responses to HBsAg are H-2 
haplotype restricted and under the control of complex MHC 
class II region genes (1). It was therefore of great interest 
to us to determine if this pattern of restriction also applied 
to the responses generated by an antiqd that mimics the group- 
spedfic a determinant on HBsAg. The studies presented here 
show that the B and T cell responses induced by our anti-Id 
2F10 are apparently not restricted by the MHC haplotypes 
that we have tested, in that all mice immunized with 2F10 
anti-Id, including the I-IBsAg nonresponder B10.M strain 
(H-2f),  made  anti-HBs  responses. These  responses were 
spedfic for the a determinant, and the anti-HBs antibodies 
carried the Id to which the immunizing anti-Id had been 
raised (data not shown). Thus, 2F10 anti-Id was successful 
in circumventing  S region nonresponsiveness in B10.M mice. 
The magnitude of the anti-FIBs response induced by our anti- 
Id varied, with SWP, and BALB/c diciting a higher anti-HBs 
titer than B10.M and M. spretus. It should be noted that in 
our experiments the anti-Id was not coupled to any carrier 
protein for the induction of anti-HBs antibodies. Therefore, 
our anti-Id must contain both B and T ceils  epitopes to achieve 
this response. Milich et al. (13) were also able to circumvent 
S region nonresponsiveness in B10.M mice by activation of 
the Th cell response to the pre $1 antigen, which could pro- 
vide help not only to pre S1 specific but also to S-specific 
B cells with subsequent  production of antibodies to the S 
region. This response, however, was not directed to the a 
determinant epitope. 
Besides being able to induce an anti-HBs response, 2F10 
anti-Id was also capable of priming in vivo T  cells from 
SWR/J,  BALB/c, and M. spretus that could subsequently 
proliferate in vitro to both anti-Id and HBsAg. The synthetic 
peptide S(139-147), which represents a partial a determinant 
epitope, could also stimulate anti-Id-primed T cells in vitro, 
further demonstrating the fidelity with which our anti-Id 
mimics the a determinant. It has been shown by others that 
Table  5.  The Effect on  T  Cell Proliferation after Treatment of APC with Anti-Ia Reagents 
APC  treatment 
rHBsAg-primed T cells  Anti-Id-primed T  cells 
Stimulus  Concentration  No  treatment  Anti-I-A  d  Anti-I-E  d  No  treatment  Anti-I-A  a  Anti-I-E  a 
/2  g  /wetl 
2F10  50  59,132  3,090  43,867  65,920  1,537  56,101 
2C3  50  716  412  390  655  294  562 
rHBsAg  0.1  82,405  2,505  81,327  54,228  396  35,678 
Peptide S(139-147)  0.1  42,571  3,400  48,373  43,873  346  21,544 
Control Peptide  0.1  ND  ND  ND  563  256  421 
Media  408  346  627  189  343  461 
In vitro proliferation  of T cells primed with either rHBsAg or 2F10 anti-Id are restricted  at the I-A  a locus in BALB/c mice. This is seen by the 
significant decrease of proliferation  in cultures  treated with MK-D6 (anti-I-A  d antibody)  versus those treated  with 34-1-4S (anti-I-E  d antibody)  or 
no treatment. Proliferation was assessed as described in Materials and Methods.  Results are expressed as the average cpm of [3H]TdK incorporation 
of two separate experiments. 
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(15-18). Thus, in the reovirus system, Sharpe et al. (16) have 
demonstrated that an internal image anti-Id that was raised 
against an antireovirus type 3 mAb could trigger T cell im- 
munity (delayed type hypersensitivity and CTL responses) 
to reovirus type 3 in naive mice. 
From the experiments presented in this report it appears 
that the anti-Id is activating T cells through the same mech- 
anisms used by nominal antigen. That is,  stimulation of 
HBsAg/anti-Id-primed T cells by either HBsAg or anti-Id 
is accessory cell dependent and needs to be processed  and 
presented to the T  cells by APC in the context of class II 
MHC molecules. The in vitro proliferation that is observed 
using monovalent Fab fragments or isolated H  chains rules 
out the possibility that our anti-Id is causing proliferation 
of these primed cells by crosslinking receptors on the T cells, 
as has been described with the anti-CD3 antibody (19). This 
is consistent with other reports of anti-Id activating antigen- 
primed T cells (17, 18). Kees et al. (17) have shown that a 
rabbit  anti-Id that mimics a 38-kD protein purified from 
Mycobacterium tuberculosis could stimulate human PBL obtained 
from either M. tuberculosis patients or BCG-vaccinated indi- 
viduals.  It was determined that the proliferation elicited by 
the anti-Id was MHC restricted and dependent on interac- 
tion with APC (18). 
It is interesting to note that the separation of intact anti- 
Id 2F10 into separate H and L chains revealed that the T cell 
epitope was located on the H chain since T cell proliferation 
to isolated H chains but not L chains was found to be com- 
parable to that dicited by intact anti-Id. It is possible that 
the T cell stimulatory epitope on the H chain of the anti-Id 
also represents the B cell epitope. The above observations of 
2F10 anti-Id mimicking  HBsAg-specific B and T cell responses 
correlate well with recent data from our laboratory. Reducing 
SDS-PAGE followed by Western blot analysis revealed that 
the expression of the internal image epitope on anti-Id 2F10 
was mainly localized to the H chain of the anti-Id, mRNA 
sequencing and molecular modeling experiments revealed an 
area of homology between the H chain and protective a de- 
terminant  epitopes of HBsAg.  A  synthetic peptide that 
represents this region of homology can duplicate the B and 
T cell stimulatory responses of the intact anti-Id and the an- 
tigen that is mimicked, HBsAg (19a). Additional support for 
T cell stimulatory epitopes also representing B cell epitopes 
comes from the influenza hemagglutinin system. It was ob- 
served that all of the hemagghtinin (HA1)  synthetic pep- 
tides recognized by CD4 + T cell clones (specific for the HA 
of X31 virus [H3N2 subtype]) corresponded to residues that 
were contained within the primary sequence of HA1 B cell 
epitopes identified as a result of their recognition by neu- 
tralizing antibody(20). 
Somewhat surprisingly, although 2F10 anti-Id generated 
an anti-HBs response in B10.M mice, it conld not prime T 
cells that can be stimulated in vitro with HBsAg. This inert- 
ness of HBsAg in B10.M may be explained by the fact that: 
(a) B10.M mice may have a limited T cell repertoire that is 
lacking recognition structures with reasonable  affinity  for 
HBsAg/MHC combination (T ceU hole);  or (b) APC of 
B10.M mice may not process or present HBsAg in such a 
way that it can be recognized by anti-Id-primed T cells. These 
issues are being further explored. Preliminary data from this 
laboratory indicate that the reason anti-Id-primed B10.M T 
cells are unable to respond in vitro to HBsAg may be due 
to low affinity binding of the a determinant peptide to MHC 
class II molecules on B10.M APC (21). An alternative view 
for the inability of HBsAg to stimulate in vitro 2F10 anti-Id- 
primed B10.M T  cells may be found in the work done in 
the GL antigen system (22). The synthetic random copolymer 
t-ghtamic add t-lysine (GL) is reported to be weakly or nonim- 
munogenic in all inbred strains of mice. Upon immunizing 
mice with the antigen poly(t-Glu t-Lys t-Tyr) (GLT), no in 
vitro response was observed when these primed T cells were 
stimulated with the antigen GL. However, after cloning these 
GLT-primed T cells, GL-reactive cells could be isolated at a 
high frequency. The same may be true with anti-Id-primed 
B10.M T  cells. 
Although we do not envision the use of anti-Ids to replace 
conventional vaccines, there may, however, be certain niches 
where anti-Ids would be very useful, for example, in individ- 
uals who are nonresponders to the licensed HBV vaccine. Ac- 
cording to some reports the immune response to the HBV 
vaccine in humans paralld those reported by Milich (1) and 
colleagues in mice, in that the response to HBsAg in both 
humans and mice are MHC linked. In mice, nonresponsive- 
ness to the S protein of HBsAg is associated with theH-2  f,* 
haplotype, while in humans it is associated with the extended 
haplotype HLA-B8,SC01,DK3  and  HLA-B44,FC31,DR7 
(23-25). The anti-HBs response that was dicited in the B10.M 
mouse strain by immunizing with anti-Id suggests that this 
anti-Id may be useful in nonresponder individuals.  The fact 
that our anti-Id is able to elicit HBsAg-specific cellular and 
humoral responses  in the outbred strain M.  spretus is en- 
couraging, since humans represent a genetically outbred popu- 
lation. An anti-Id vaccine consisting of an invariant T  cell 
epitope and an appropriate B cell epitope might well induce 
specific cellular and humoral immunity in a genetically di- 
verse human population. Further, the sharing of Ids of related 
specificity between T  and B cells would permit the use of 
the same anti-Id to activate both B and T cells for an anam- 
nestic recognition of similar epitopes on the infectious or- 
ganism. 
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